EU and US could reach trade deal this weekend - Reuters
NEW YORK - Goldman Sachs & Co (NYSE:GS). LLC has disclosed a change in its holdings in Mural Oncology PLC, as per a recent filing with the Irish Takeover Panel. The transaction involved a mix of long and short positions in the company’s USD 0.01 ordinary shares, with dealings recorded on Wednesday.
According to the disclosure, Goldman Sachs now holds a long position of 90,971 shares, representing approximately 0.52% of Mural Oncology, and a short position of 183,668 shares, representing around 1.06%. Additionally, the investment bank holds another long position through derivatives, with 89,372 shares, or 0.51%.
The only specific transaction reported on April 30 was a sale of one share at a price of $2.6250. The filing also noted a purchased swap derivative with a relation to one relevant security, but with no exercise price, as it is not applicable. This derivative is set to expire on July 8, 2025.
Goldman Sachs confirmed that there are no agreements, arrangements, or understandings relating to options or derivatives connected to the voting rights of any relevant securities. Furthermore, the filing indicated that a supplemental Form 8 was attached, although the details of this supplemental form were not disclosed in the press release.
This activity comes amid regular reporting requirements for entities holding interests in securities representing 1% or more, in the context of the Irish Takeover Panel Act, 1997, and the Takeover Rules, 2013. The disclosure was made by Goldman Sachs on May 1, 2025, with contact names provided for Papa Lette and Andrzej Szyszka, along with their respective telephone numbers.
The information in this article is based on a press release statement and provides a snapshot of Goldman Sachs’ dealings with Mural Oncology PLC as required by regulatory obligations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.